In line with this, the analysis of clinic-pathological parameters in the much larger TARGET cohort, consisting of 264 patients with T-ALL, revealed an additional correlation between NFE2L2 expression and the TLX3 molecular subgroup, which is a reported poor outcome factor (reviewed in [6]). This evidence concerns the gene NFE2L2 and acute lymphoblastic leukemia.